Article Text

Download PDFPDF
Diagnostic accuracy of serum insulin-like growth factor-binding protein 2 for ovarian cancer
  1. Pande Kadek Aditya Prayudi,
  2. I Nyoman Gede Budiana,
  3. Putu Doster Mahayasa,
  4. I Gede Ngurah Harry Wijaya Surya,
  5. Anak Agung Gede Putra Wiradnyana and
  6. Ketut Suwiyoga
  1. Department of Obstetrics and Gynecology, Udayana University Faculty of Medicine/Sanglah General Hospital, Denpasar, Bali, Indonesia
  1. Correspondence to Dr Pande Kadek Aditya Prayudi, Department of Obstetrics and Gynecology, Udayana University Faculty of Medicine/Sanglah General Hospital, Bali 80234, Indonesia; prayudipande{at}yahoo.com

Abstract

Introduction Insulin-like growth factor-binding protein 2 (IGFBP2) plays an important role in the pathogenesis of ovarian cancer. The most prominent effects of IGFBP2 include promoting proliferation, driving invasion, and suppressing apoptosis. This study aimed to determine the diagnostic accuracy of serum IGFBP2 in differentiating between benign and malignant ovarian neoplasms.

Methods Preoperative serum IGFBP2 level was evaluated from 76 women with primary ovarian tumor who underwent exploratory laparotomy at Sanglah General Hospital, Denpasar, Bali, Indonesia. The optimal threshold value of IGFBP2 for the diagnosis of ovarian cancer was determined from the receiver 0perating characteristic (ROC) curve. The diagnosis was confirmed by histopathologic analysis of resected ovarian specimens.

Results Forty-six (60.5%) patients were diagnosed with ovarian cancer. The area under the ROC curve (AUC) of IGFBP2 in detecting ovarian cancer was 0.815 (95% CI: 0.721 to 0.910, P<0.001). For a given specificity larger than 95%, the optimal sensitivity was 63%. The optimal threshold value of IGFBP2 for the diagnosis of ovarian cancer was 804 ng/mL [sensitivity 63%, specificity 96.7%, positive predictive value (PPV) 96.7%, negative predictive value (NPV) 63%, accuracy 76.3%, and diagnostic odd ratio (DOR) 49.5 (95% CI 6.1 to 396.5)]. In a subgroup analysis, IGFBP2 showed excellence performance in diagnosing advanced ovarian cancer (AUC 0.904 [95% CI: 0.806 to 1.000], sensitivity 83.3%, specificity 96.7%, PPV 95.2%, NPV 87.9%, accuracy 90.7%, and DOR 145.0 [95% CI 15.0 to 1395.3]).

Conclusion IGFBP2 is a novel and potentially promising biomarker for detecting ovarian cancer. Further studies are needed to confirm its diagnostic performance in premenopausal women and for detecting early stage ovarian cancer.

  • ovarian cancer
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Prayudi, PKA: Conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, statistical analysis. Budiana, ING: Conception and design, analysis and interpretation of data, administrative, technical, or material support. Mahayasa, PD: Conception and design, administrative, technical, or material support. Surya, IGNH: Conception and design, administrative, technical, or material support. Wiradnyana, AAGP: Conception and design, administrative, technical, or material support. Suwiyoga, K: Supervision, administrative, technical, or material support.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.